Sanofi (NASDAQ:SNY) Shares Purchased by NewEdge Advisors LLC

NewEdge Advisors LLC grew its holdings in shares of Sanofi (NASDAQ:SNY) by 27.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 29,587 shares of the company’s stock after purchasing an additional 6,330 shares during the quarter. NewEdge Advisors LLC’s holdings in Sanofi were worth $1,436,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in SNY. Crossmark Global Holdings Inc. lifted its holdings in shares of Sanofi by 2.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 36,274 shares of the company’s stock worth $1,803,000 after acquiring an additional 869 shares during the period. Connectus Wealth LLC acquired a new position in shares of Sanofi in the 4th quarter valued at $828,000. Logan Capital Management Inc. grew its stake in shares of Sanofi by 3.4% during the 4th quarter. Logan Capital Management Inc. now owns 71,259 shares of the company’s stock valued at $3,544,000 after buying an additional 2,356 shares during the period. Strategic Global Advisors LLC raised its position in shares of Sanofi by 25.6% in the 4th quarter. Strategic Global Advisors LLC now owns 7,345 shares of the company’s stock worth $365,000 after buying an additional 1,496 shares during the period. Finally, Putnam Investments LLC raised its holdings in shares of Sanofi by 25.9% in the 4th quarter. Putnam Investments LLC now owns 1,342,709 shares of the company’s stock worth $66,773,000 after purchasing an additional 276,259 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on SNY. Argus lifted their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Stock Down 0.1 %

Shares of Sanofi stock opened at $55.47 on Friday. The firm has a market cap of $140.76 billion, a P/E ratio of 27.87, a P/E/G ratio of 1.58 and a beta of 0.60. The business has a 50-day moving average price of $55.52 and a 200 day moving average price of $51.09. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. Sanofi’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.95 earnings per share. On average, sell-side analysts forecast that Sanofi will post 4.26 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.